Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selonsertib + prednisolone
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selonsertib + prednisolone is an oral combination therapy evaluated in clinical trials for the treatment of severe alcoholic hepatitis. **Selonsertib** is a first-in-class, selective, and potent small-molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1/MAP3K5), a kinase involved in cellular stress responses, inflammation, and fibrosis. **Prednisolone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, commonly used as standard of care for severe alcoholic hepatitis. The combination has been studied to determine whether selonsertib could enhance the efficacy of prednisolone in reducing liver injury and improving outcomes in severe alcoholic hepatitis patients[1][2][3][4][6][8].
- Other names
- selonsertib + prednisolone
02
Targets
GR (Glucocorticoid receptor)MAP3K5 (ASK1)
Beyond the preview
Go deeper on selonsertib + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selonsertib + prednisolone.